Drug giant GlaxoSmithKline is joining the Bill & Melinda Gates Foundation, JPMorgan Chase, other firms and other individual investors in launching a $94 million global fund that will focus on combating diseases.
The launch of the Global Health Investment Fund was disclosed early Monday.
Noted Dr. Moncef Slaoui, chairman Vaccines and R&D at GSK (Nyse: GSK): "I am convinced the GHIF will be instrumental in helping bring cutting edge innovation and solutions to diseases of the developing world and this is one reason why we are participating. This collaboration demonstrates that with an innovative structure, a fund with a humanitarian focus can appeal to a broader range of investors."